- Home
- MNOV vs CODA Comparison
MNOV vs CODA Comparison
Compare MNOV & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | CODA |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 134.4M |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MNOV | CODA |
|---|---|---|
| Price | $1.40 | $11.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 17.8K | ★ 94.3K |
| Earning Date | 05-14-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.62 |
| EPS | N/A | ★ 0.08 |
| Revenue | $2,360,807.00 | ★ $20,316,161.00 |
| Revenue This Year | N/A | $18.28 |
| Revenue Next Year | $180.00 | $12.62 |
| P/E Ratio | ★ N/A | $142.75 |
| Revenue Growth | ★ 194.15 | 4.98 |
| 52 Week Low | $1.17 | $5.98 |
| 52 Week High | $1.96 | $18.00 |
Technical Indicators
Market Signals| Indicator | MNOV | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 50.19 |
| Support Level | $1.35 | $10.81 |
| Resistance Level | $1.43 | $12.24 |
| Average True Range (ATR) | 0.03 | 0.43 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.00 | 66.67 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.